Sino Biopharmaceutical Acquires Hangzhou Hygieia Biomedical
January 14, 2026
Source: drugdu
37
On January 13, Hong Kong-listed pharmaceutical leader Sino Biopharmaceutical (1177.HK) issued an announcement, declaring the full acquisition of domestic siRNA innovative drug company Hangzhou Hygieia Biomedical for a total price of RMB 1.2 billion.
According to available data, Hygieia Biomedical was established in 2018 and is committed to providing innovative siRNA products with ultra-long action and low dosage advantages. The core R&D team, led by founder and chief scientist Dr. Cui Kunyuan, possesses over 20 years of professional experience in the development of small nucleic acid drugs, securing more than 50 core patents covering multiple delivery systems.
Leveraging this profound technical accumulation, Hygieia has established six major intrahepatic and extrahepatic delivery platforms. Currently, four innovative drug candidates have advanced into the clinical stage, with over 20 projects in the preclinical phase, and the company has achieved two external licensing agreements. These pipelines hold significant potential as global First-in-Class (FIC) and Best-in-Class (BIC) therapies.
https://finance.eastmoney.com/a/202601143618121375.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- First Dry Powder Inhaler from a Chinese Pharmaceutical Company Approved by FDA for U.S. Marketing January 14, 2026
- U.S. FDA Accepts Investigational New Drug (IND) Application for LAE118 January 14, 2026
- Another boost to domestically developed vaccines! Baihui Biotechnology’s human diploid cell rabies vaccine approved for clinical trials January 14, 2026
- Eli Lilly’s oral weight loss drug has been submitted for marketing approval in China January 14, 2026
- Isaconazole sulfate API approved for market launch, expanding into the antifungal drug field January 14, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
